Legend Biotech (LEGN) investor relations material

Opening remarks and company overview

• Highlighted leadership in cell therapy and CAR T for multiple myeloma, with CARVYKTI as a flagship product and fastest commercial launch among CAR T therapies, generating nearly $2 billion in 2025 sales.

• Over 10,000 patients treated with CARVYKTI globally; company expects to achieve corporate profitability this year with $835 million in liquidity.

• Pipeline includes 14 programs, with upcoming data on in vivo CAR T for non-Hodgkin's lymphoma.

Clinical data and curative potential

• IMWG proposed a new definition of cure in multiple myeloma: sustained MRD negativity for five years without therapy, supported by CARTITUDE-1 data.

• One-third of CARTITUDE-1 patients were treatment- and progression-free for over five years after a single infusion, with sustained MRD and PET negativity.

• Median overall survival in CARTITUDE-1 was 61 months, a fivefold improvement over historical controls.

Early treatment and efficacy

• Earlier use of CARVYKTI leads to higher response rates, longer progression-free and overall survival, and improved safety, especially when used in second line.

• CARTITUDE-4 data show median PFS not reached at 30 months in lenalidomide-refractory patients; real-world data confirm better outcomes with earlier CAR T.

• Manufacturing success rate is 99% in earlier lines due to fitter T cells and less inflammatory burden.